42 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Benzimidazolone bioisosteres of potent GluN2B selective NMDA receptor antagonists.
Institut F£R Pharmazeutische Und Medizinische Chemie Der Universit£T M£Nster
Synthesis, GluN2B affinity and selectivity of benzo[7]annulen-7-amines.
Institut F£R Pharmazeutische Und Medizinische Chemie Der Universit£T M£Nster
A novel series of benzimidazole NR2B-selective NMDA receptor antagonists.
Glaxosmithkline
2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.
Astrazeneca Pharmaceuticals
Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA/NR2B antagonists.
Merck Research Laboratories
Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonists.
Merck Research Laboratories
Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.
Merck Research Laboratories
Discovery of Potent Cholinesterase Inhibition-Based Multi-Target-Directed Lead Compounds for Synaptoprotection in Alzheimer's Disease.
Yeditepe University
Orally efficacious NR2B-selective NMDA receptor antagonists.
Merck Research Laboratories
3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity.
Merck Research Laboratories
Ifenprodil Stereoisomers: Synthesis, Absolute Configuration, and Correlation with Biological Activity.
Westf£Lische Wilhelms-Universit£T M£Nster
Negative allosteric modulators of the GluN2B NMDA receptor with phenylethylamine structure embedded in ring-expanded and ring-contracted scaffolds.
Institut F£R Pharmazeutische Und Medizinische Chemie Der Universit£T M£Nster
Synthesis, Cytotoxicity Evaluation, and Computational Insights of Novel 1,4-Diazepane-Based Sigma Ligands.
University of Trieste
Thiophene bioisosteres of GluN2B selective NMDA receptor antagonists: Synthesis and pharmacological evaluation of [7]annuleno[b]thiophen-6-amines.
Westf£Lische Wilhelms-Universit£T M£Nster
Parallel synthesis of a series of subtype-selective NMDA receptor antagonists.
Parke-Davis Pharmaceutical Research
Tetrahydro-3-benzazepines with fluorinated side chains as NMDA and ?
Institut F£R Pharmazeutische Und Medizinische Chemie Der Universit£T M£Nster
Modification of the 4-phenylbutyl side chain of potent 3-benzazepine-based GluN2B receptor antagonists.
Institut F£R Pharmazeutische Und Medizinische Chemie Der Universit£T M£Nster
Positive and Negative Allosteric Modulators of N-Methyl-d-aspartate (NMDA) Receptors: Structure-Activity Relationships and Mechanisms of Action.
University of Bristol
Benzo[7]annulene-based GluN2B selective NMDA receptor antagonists: Surprising effect of a nitro group in 2-position.
University Munster
Hydroxymethyl bioisosteres of phenolic GluN2B-selective NMDA receptor antagonists: Design, synthesis and pharmacological evaluation.
Institut F£R Pharmazeutische Und Medizinische Chemie Der Universit£T M£Nster
Synthesis, Receptor Affinity, and Antiallodynic Activity of Spirocyclic ? Receptor Ligands with Exocyclic Amino Moiety.
Universit£T M£Nster
BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder.
Bristol-Myers Squibb Research and Development
Characterization of [3H]quinpirole binding to D2-like dopamine receptors in rat brain.
Dupont Pharmaceuticals
Identification of novel chemical inhibitors for ubiquitin C-terminal hydrolase-L3 by virtual screening.
Waseda University
Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex.
Pharmacia
Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.
Bristol-Myers Squibb Pharmaceutical Research Institute